| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -26,237 | -16,182 | -14,181 | -32,875 |
| Stock-based compensation expense | 2,824 | 1,946 | 2,189 | 3,973 |
| Depreciation and amortization | NaN | NaN | NaN | 340 |
| Depreciation | 184 | 157 | 504 | NaN |
| Non-cash research and development license expense | NaN | 0 | 0 | 0 |
| Non-cashinterest expense related to term loan | 206 | 175 | 192 | 362 |
| Non-cashlease expense | 200 | 197 | 195 | 382 |
| Loss on disposal of assets | -9 | 0 | -114 | -42 |
| Change in other, net | 116 | 91 | 112 | 124 |
| Loss on extinguishment of debt | 0 | 0 | 0 | -681 |
| Prepaid expenses and other assets | 4,130 | -656 | -628 | 1,183 |
| Accounts payable | 1,490 | -297 | 461 | 57 |
| Accrued liabilities and other liabilities | -1,753 | 1,741 | 208 | -2,238 |
| Net cash used in operating activities | -27,091 | -11,516 | -9,918 | -30,335 |
| Capital expenditures | 556 | 0 | 0 | 24 |
| Net cash used in investing activities | -556 | 0 | 0 | -24 |
| Proceeds from sale of common stock and pre-funded warrants in 2026 private placement | 120,000 | 50,000 | NaN | NaN |
| Payments from sale of common stock and pre-funded warrants in 2026 private placement | 4,875 | 167 | NaN | NaN |
| Proceeds from issuance of common stock from initial public offering | NaN | 0 | 0 | 0 |
| Payments of issuance costs-Series BAnd Series CPreferred Stock | NaN | 0 | NaN | NaN |
| Proceeds from convertible grant agreement | NaN | 0 | 0 | 750 |
| Payments of issuance costs-IPO | NaN | 0 | 0 | 0 |
| Payment of withholding taxes for stock-based compensation | 190 | NaN | NaN | NaN |
| Payments on issuance cost from registration statement | 0 | 0 | 0 | 556 |
| Proceeds from issuance of term loan, net | 0 | 0 | 0 | 19,688 |
| Payments on issuance costs-Series CPreferred Stock Financing | NaN | NaN | 0 | 0 |
| Repayment of former term loan | 0 | 0 | 0 | 10,213 |
| Payment of loan financing cost | 0 | 0 | 0 | 127 |
| Proceeds from exercise of stock options | 6 | 352 | 153 | 198 |
| Net cash provided by financing activities | 114,941 | 50,185 | 153 | 9,740 |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | -16 | -1 | -4 | -25 |
| Net (decrease) increase in cash, cash equivalents and restricted cash | 87,278 | 38,668 | -9,769 | -20,644 |
| Cash, cash equivalents and restricted cash at the beginning of the period | 176,984 | 138,316 | 168,729 | NaN |
| Cash, cash equivalents and restricted cash at the end of the period | 264,262 | 176,984 | 138,316 | NaN |
Alto Neuroscience, Inc. (ANRO)
Alto Neuroscience, Inc. (ANRO)